{"entity":{"id":"nct04888312","kind":"trial","name":"Safety and Efficacy of Mitazalimab in Combination With Chemotherapy in Pancreatic Cancer Patients","aka":[],"tldr":"A phase 1/2 trial of CD40 agonist mitazalimab in combination with chemotherapy in pancreatic ductal adenocarcinoma, run by Alligator Bioscience AB, active and no longer recruiting.","summary":"Safety and Efficacy of Mitazalimab in Combination With Chemotherapy in Pancreatic Cancer Patients is a phase 1/2 interventional study registered as NCT04888312 by Alligator Bioscience AB, with 94 participants enrolled, started 2021-09-17 and due to reach its primary completion in 2026-06-01. Interventions recorded: CD40 agonist mitazalimab in combination with chemotherapy.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT04888312","url":"https://clinicaltrials.gov/study/NCT04888312"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["pancreatic"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT04888312","phase":"1/2","setting":"An Open-label Phase 1b/2 Study Assessing the Safety and Efficacy of Mitazalimab in Combination With Chemotherapy in Patients With Metastatic Pancreatic Ductal Adenocarcinoma","sponsor":"Alligator Bioscience AB","enrolled":94,"outcomes":[]},"route":"/trials/nct04888312/","neighbours":{"cancer":[{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/"}],"drug":[{"id":"mitazalimab","kind":"drug","name":"Mitazalimab","route":"/drugs/mitazalimab/"}]}}